Merck Provides Update on Phase 3 KEYNOTE-119 Study of KEYTRUDA® (pembrolizumab) Monotherapy in Previously-Treated Patients with Metastatic Triple-Negative Breast Cancer

KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced that the Phase 3 KEYNOTE-119 trial evaluating KEYTRUDA,
Merck’s anti-PD-1 therapy, as monotherapy for the second- or third-line
treatment of patients with metastatic triple-negative breast cancer
(TNBC) did not meet its pre-specified primary endpoint of superior
overall survival (OS) compared to chemotherapy (capecitabine, eribulin,
gemcitabine or vinorelbine).

read more

Read Original Article: Merck Provides Update on Phase 3 KEYNOTE-119 Study of KEYTRUDA® (pembrolizumab) Monotherapy in Previously-Treated Patients with Metastatic Triple-Negative Breast Cancer »